OSE Immunotherapeutics announces the appointment of Dominique Costantini as interim Chief Executive Officer following the departure of Alexis Peyroles – 01/17/2022 at 07:30


Nantes, France – January 17, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the departure of Alexis Peyroles as Chief Executive Officer of the Company. Dominique Costantini, currently Chairman of the Board of Directors of OSE Immunotherapeutics and Chief Executive Officer from 2012 to 2018, has been appointed Interim Chief Executive Officer, effective immediately. The search for a new Managing Director has started with the help of a leading international recruitment firm.



Source link -86